Anti-D Rho immunoglobulin - Bharat Serums and Vaccines

Drug Profile

Anti-D Rho immunoglobulin - Bharat Serums and Vaccines

Alternative Names: Anti-D immunoglobulin (monoclonal); Rhoclone

Latest Information Update: 13 Apr 2017

Price : $50

At a glance

  • Originator Bharat Serums and Vaccines
  • Class Immunoglobulins
  • Mechanism of Action Immunoglobulin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemolytic disease of newborn

Most Recent Events

  • 30 Mar 2017 Bharat Serums and Vaccines completes a phase III trial for Hemolytic disease of newborn in India (CTRI2015-09-006172) prior to March 2017
  • 15 Mar 2017 Bharat Serum and Vaccines plans a phase II/III trial for Haemolytic disease of newborn (Prevention) in India (CTRI/2017/03/008101)
  • 31 Aug 2016 Launched for Haemolytic disease of newborn (Prevention) in India (IM) before August 2016 (Bharat Serums and Vaccines Pipeline, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top